These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 126948)

  • 1. Human plasminogen: a summary of studies on its isolation, characterization and activation mechanism.
    Rickli EE
    Immunochemistry; 1975 Jul; 12(6-7):629-32. PubMed ID: 126948
    [No Abstract]   [Full Text] [Related]  

  • 2. The mechanism of activation of rabbit plasminogen by urokinase. Lack of a preactivation peptide.
    Sodetz JM; Brockway WJ; Mann KG; Castellino FJ
    Biochem Biophys Res Commun; 1974 Sep; 60(2):729-36. PubMed ID: 4278813
    [No Abstract]   [Full Text] [Related]  

  • 3. Structural relationship between "glutamic acid" and "lysine" forms of human plasminogen and their interaction with the NH2-terminal activation peptide as studied by affinity chromatography.
    Wiman B; Wallén P
    Eur J Biochem; 1975 Jan; 50(3):489-94. PubMed ID: 122932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two distinct pathways of the streptokinase-mediated activation of highly purified human plasminogen.
    McClintock DK; Englert ME; Dziobkowski C; Snedeker EH; Bell PH
    Biochemistry; 1974 Dec; 13(26):5334-44. PubMed ID: 4279693
    [No Abstract]   [Full Text] [Related]  

  • 5. Isolation of plasmin-free human plasminogen with N-terminal glutamic acid.
    Rickli EE; Cuendet PA
    Biochim Biophys Acta; 1971 Nov; 250(2):447-51. PubMed ID: 5143348
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoclonal antibodies inhibitory to human plasmin. Definitive demonstration of a role for plasmin in activating the proenzyme of urokinase-type plasminogen activator.
    Sim PS; Fayle DR; Doe WF; Stephens RW
    Eur J Biochem; 1986 Aug; 158(3):537-42. PubMed ID: 2942403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen.
    Wallén P; Wiman B
    Biochim Biophys Acta; 1972 Jan; 257(1):122-34. PubMed ID: 4257942
    [No Abstract]   [Full Text] [Related]  

  • 8. Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound.
    Wiman B; Wallén P
    Eur J Biochem; 1973 Jul; 36(1):25-31. PubMed ID: 4270055
    [No Abstract]   [Full Text] [Related]  

  • 9. Physico-chemical and proenzyme properties of NH2-terminal glutamic acid and NH2-terminal lysine human plasminogen. Influence of 6-aminohexanoic acid.
    Claeys H; Vermylen J
    Biochim Biophys Acta; 1974 Apr; 342(2):351-9. PubMed ID: 4275496
    [No Abstract]   [Full Text] [Related]  

  • 10. The reciprocal effects of epsilon-aminohexanoic acid and chloride ion on the activation of human [Glu1]plasminogen by human urokinase.
    Urano T; Chibber BA; Castellino FJ
    Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4031-4. PubMed ID: 3473492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease inhibitors and human plasmin: interaction in a whole plasma system.
    Highsmith RF; Weirich CJ; Burnett CJ
    Biochem Biophys Res Commun; 1977 Dec; 79(3):648-56. PubMed ID: 145863
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterization of human plasminogen. I. On the relationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparations.
    Wallén P; Wiman B
    Biochim Biophys Acta; 1970 Oct; 221(1):20-30. PubMed ID: 4248689
    [No Abstract]   [Full Text] [Related]  

  • 13. The activation mechanism of human plasminogen.
    Rickli EE
    Thromb Diath Haemorrh; 1975 Nov; 34(2):386-95. PubMed ID: 128150
    [No Abstract]   [Full Text] [Related]  

  • 14. Fibrinolytic inhibitors in human seminal plasma.
    Liedholm P; Astedt B
    Experientia; 1974 Oct; 30(10):1113-4. PubMed ID: 4279828
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of epsilon-amino caproic acid on the gross conformation of plasminogen and plasmin.
    Violand BN; Sodetz JM; Castellino FJ
    Arch Biochem Biophys; 1975 Sep; 170(1):300-5. PubMed ID: 126043
    [No Abstract]   [Full Text] [Related]  

  • 16. The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation.
    Sun Z; Chen YH; Wang P; Zhang J; Gurewich V; Zhang P; Liu JN
    Biochim Biophys Acta; 2002 Apr; 1596(2):182-92. PubMed ID: 12007600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of a low molecular weight form of plasminogen.
    Paoni NF; Castellino FJ
    Biochem Biophys Res Commun; 1975 Jul; 65(2):757-64. PubMed ID: 125089
    [No Abstract]   [Full Text] [Related]  

  • 18. Evidence for high-molecular weight active peptides originating from porcine plasmin autolysis.
    Grimard M
    Biochimie; 1976; 58(11-12):1409-12. PubMed ID: 138450
    [No Abstract]   [Full Text] [Related]  

  • 19. Release of an N-terminal peptide from human plasminogen during activation with urokinase.
    Rickli EE; Otavsky WI
    Biochim Biophys Acta; 1973 Jan; 295(1):381-4. PubMed ID: 4685077
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
    Jiao J; Yu M; Ru B
    Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.